Note 16 - Quarterly Financial Information (Unaudited) - Financial Statement Reclassification (Details) - USD ($)		3 Months Ended																6 Months Ended				9 Months Ended				12 Months Ended
		Sep. 30, 2019		Jun. 30, 2019		Mar. 31, 2019		Mar. 30, 2019		Sep. 30, 2018		Jun. 30, 2018		Mar. 31, 2018		Mar. 30, 2018		Jun. 30, 2019		Jun. 30, 2018		Sep. 30, 2019		Sep. 30, 2018		Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Sep. 30, 2019		Jun. 30, 2019		Mar. 31, 2019		Mar. 30, 2019	Jan. 01, 2019	Dec. 31, 2018	Sep. 30, 2018		Jun. 30, 2018		Mar. 31, 2018		Mar. 30, 2018	Jan. 01, 2018	Dec. 31, 2017
Cash and cash equivalents		$ 21,205,000		$ 19,617,000		$ 31,824,000		$ 31,824,000		$ 32,381,000		$ 14,167,000		$ 7,033,000		$ 7,033,000		$ 19,617,000		$ 14,167,000		$ 21,205,000		$ 32,381,000		$ 30,657,000	$ 6,663,000	$ 6,448,000	$ 21,205,000		$ 19,617,000		$ 31,824,000		$ 31,824,000		$ 30,657,000	$ 32,381,000		$ 14,167,000		$ 7,033,000		$ 7,033,000		$ 6,663,000
Accounts receivable, trade, net of allowance for doubtful accounts of $68 and $0 at December 31, 2019 and 2018, respectively																												5,345,000	4,313,000		3,832,000		2,927,000				3,045,000	2,699,000		2,166,000		1,043,000
Inventories																												10,972,000	5,694,000		5,306,000		4,060,000				3,509,000	2,911,000		2,122,000		1,837,000
Prepaid expenses and other current assets																												1,348,000	855,000		384,000		346,000				353,000	298,000		352,000		331,000
Total current assets																												24,113,000	32,067,000		29,139,000		39,157,000				37,564,000	38,289,000		18,807,000		10,244,000
Leasehold improvements																													1,599,000		1,284,000		1,284,000					1,284,000		1,284,000		1,284,000
Furniture and computer equipment																													588,000		577,000		704,000					706,000		693,000		692,000
Manufacturing and other equipment																													2,247,000		1,733,000		1,803,000					1,511,000		1,230,000		1,195,000
Subtotal																												8,093,000	4,434,000		3,594,000		3,791,000				3,647,000	3,501,000		3,207,000		3,171,000
Less: Accumulated depreciation																												(2,521,000)	(2,298,000)		(2,276,000)		(2,424,000)				(2,328,000)	(2,234,000)		(2,163,000)		(2,084,000)
Property and equipment, net																												5,572,000	2,136,000		1,318,000		1,367,000				1,319,000	1,267,000		1,044,000		1,087,000
Equity method investment in SAVSU																													1,000,000		6,100,000		6,317,000				6,548,000	6,857,000		1,900,000		926,000
Long-term deposits and other assets																												50,000	36,000		136,000		36,000				36,000	36,000		36,000		36,000
Total assets																												92,816,000	83,789,000		51,303,000		48,073,000				45,467,000	46,449,000		21,787,000		12,293,000
Accounts payable																												3,119,000	1,570,000		876,000		1,264,000				720,000	1,090,000		843,000		586,000
Accrued expenses and other current liabilities																												3,369,000	642,000		204,000		142,000				1,219,000	162,000		173,000		204,000
Accrued compensation																													1,576,000		963,000		630,000					713,000		518,000		392,000
Deferred rent, current portion																															1,079,000		1,196,000				130,000
Total current liabilities																												7,669,000	5,014,000		3,163,000		2,701,000				1,939,000	2,095,000		1,664,000		1,312,000
Deferred rent, long-term																																						386,000		423,000		457,000
Warrant liability																												39,602,000	41,771,000		44,194,000		48,106,000				28,516,000	50,425,000		32,599,000		14,725,000
Other long-term liabilities																												4,000	3,000		7,000		13,000				380,000	38,000		45,000		52,000
Total liabilities																												49,362,000	48,598,000		49,231,000		51,813,000				30,835,000	52,944,000		34,731,000		16,546,000
Commitments and Contingencies (Note 12)
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding at December 31, 2019 and 2018
Common stock, $0.001 par value; 150,000,000 shares authorized, 20,825,452 and 18,547,406 shares issued and outstanding at December 31, 2019 and 2018, respectively																												21,000	20,000		19,000		19,000				19,000	18,000		16,000		14,000
Additional paid-in capital																												143,485,000	138,206,000		115,357,000		113,797,000				113,008,000	112,755,000	[1]	81,762,000		64,017,000
Accumulated deficit																												(100,052,000)	(103,035,000)		(113,304,000)		(117,556,000)				(98,395,000)	(119,268,000)	[1]	(94,722,000)		(68,284,000)			$ (73,051,000)
Total shareholders’ equity																												43,454,000	35,191,000		2,072,000		(3,740,000)				14,632,000	(6,495,000)		(12,944,000)		(4,253,000)			(9,532,000)	(9,532,000)
Total liabilities and shareholders’ equity																												92,816,000	83,789,000		51,303,000		48,073,000				45,467,000	46,449,000		21,787,000		12,293,000
Lease liabilities, operating, current portion																												804,000	771,000		665,000		651,000
Lease liability - financing, current position																													14,000		14,000		14,000
Lease liabilities, operating, long-term																												550,000	753,000		806,000		980,000
Long-term lease liability - financing																													6,000		10,000		13,000
Intangible assets, net																												21,982,000	16,055,000		4,016,000
Goodwill																												33,637,000	28,342,000		9,515,000
Contingent consideration, current portion																												377,000	441,000		441,000
Contingent consideration, long term																												1,537,000	1,051,000		1,051,000
Assets held for rent, net																												3,922,000	2,976,000
Operating lease right-of-use assets, net																												1,040,000	1,177,000							$ 1,300,000
Contingent consideration - long-term																												$ 1,537,000	1,051,000		1,051,000
Revenue		6,604,000		6,701,000		5,770,000				5,293,000		5,178,000		3,815,000				12,471,000		8,993,000		19,075,000		14,286,000		27,371,000	19,742,000
Cost of product and rental revenue (exclusive of intangible assets amortization)		2,094,000		1,968,000		1,647,000				1,606,000		1,537,000		1,364,000				3,616,000		2,901,000		5,710,000		4,507,000		8,760,000	6,217,000
Research and development		1,032,000		691,000		359,000				312,000		325,000		346,000				1,050,000		671,000		2,082,000		983,000		3,168,000	1,298,000
Sales and marketing		1,250,000		945,000		837,000				725,000		641,000		612,000				1,782,000		1,253,000		3,032,000		1,978,000		4,701,000	2,615,000
General and administrative		2,348,000		2,207,000		2,153,000				1,455,000		1,390,000		1,353,000				4,359,000		2,744,000		6,707,000		4,199,000		8,893,000	5,950,000
Total operating expenses		7,376,000		5,954,000		5,204,000				4,098,000		3,893,000		3,675,000				11,158,000		7,569,000		18,534,000		11,667,000
Operating income (loss)		(772,000)		747,000		566,000				1,195,000		1,285,000		140,000				1,313,000		1,424,000		541,000		2,619,000		(220,000)	3,662,000
Change in fair value of warrant liability		1,128,000		3,586,000		19,663,000		19,663,000		25,696,000		27,485,000		4,870,000		(4,870,000)		16,077,000		22,615,000		14,949,000		48,311,000		12,835,000	28,271,000
Interest income		110,000		137,000		171,000				80,000		32,000		8,000				307,000		41,000		417,000	[1]	121,000
Interest expense		(1,000)		(1,000)		(3,000)				(1,000)		(1,000)		(1,000)				(4,000)		(1,000)		(5,000)		(4,000)
Loss from equity-method investment in SAVSU		(291,000)		(217,000)		(232,000)		(232,000)		(43,000)		(177,000)		(144,000)		(144,000)		(448,000)		(321,000)		(739,000)		(363,000)		(739,000)	(672,000)
Total other expense		11,041,000		3,505,000		(19,727,000)				(25,660,000)		(27,631,000)		4,733,000				(16,222,000)		(22,896,000)		(5,181,000)		(48,557,000)		(2,978,000)	(28,667,000)
Net loss (restated)		10,269,000		4,252,000		(19,161,000)		(19,161,000)		(24,465,000)		(26,346,000)		4,873,000		4,873,000		(14,909,000)		(21,472,000)		(4,640,000)		(45,938,000)		(1,657,000)	(25,005,000)
Less: Preferred stock dividends and accumulated deficit impact of preferred stock redemption										(80,000)		(93,000)		(106,000)						(200,000)				(279,000)			(339,000)
Net income (loss) attributable to common stockholders		8,380,000		3,425,000		(19,161,000)				(24,545,000)		(26,439,000)		4,767,000				(14,909,000)		(21,672,000)		(4,640,000)		(46,217,000)		$ (1,657,000)	$ (25,344,000)
Diluted		$ 8,862,000		$ 545,000		$ (19,161,000)				$ (24,545,000)		$ (26,439,000)		$ (282,000)				$ (14,909,000)		$ (21,672,000)		$ (4,640,000)		$ (46,217,000)
Basic (in dollars per share)		$ 0.42		$ 0.18		$ (1.03)				$ (1.42)		$ (1.74)		$ 0.22				$ (0.80)		$ (1.48)		$ (0.24)		$ (2.98)			$ (1.56)
Diluted (in dollars per share)		$ 0.35		$ 0.02		$ (1.03)				$ (1.42)		$ (1.74)		$ (0.02)				$ (0.80)		$ (1.48)		$ (0.24)		$ (2.98)			$ (1.56)
Basic (in shares)		19,735,364		18,819,459		18,648,397				17,273,412		15,180,169		14,098,610				18,734,401		14,642,378		19,071,722		15,529,026		19,460,299	16,256,465
Diluted (in shares)		25,343,112		24,539,299		18,648,397				17,273,412		15,180,169		14,098,610				18,734,401		14,642,378		19,071,722		15,529,026
Change in fair value of warrant liability		$ (1,128,000)		$ (3,586,000)		$ (19,663,000)		(19,663,000)		$ (25,696,000)		$ (27,485,000)		$ (4,870,000)		4,870,000		$ (16,077,000)		$ (22,615,000)		$ (14,949,000)		$ (48,311,000)		$ (12,835,000)	$ (28,271,000)
Acquisition costs		291,000		39,000		208,000												247,000				538,000				940,000
Income (loss) before provision for income taxes		10,269,000		4,252,000		(19,161,000)												(14,909,000)				(4,640,000)				(3,198,000)	(25,005,000)
Income tax (benefit)		0		0		0												0				0				(1,541,000)
Cost of product revenue (exclusive of intangible assets amortization)		2,094,000		1,968,000		1,647,000				1,606,000		1,537,000		1,364,000				3,616,000		2,901,000		5,710,000		4,507,000		8,760,000	6,217,000
Amort of Intangibles		361,000		104,000														104,000				465,000				1,079,000
Income (loss) before provision for income taxes		10,269,000		4,252,000		(19,161,000)												(14,909,000)				(4,640,000)				(3,198,000)	(25,005,000)
Income taxes		0		0		0												0				0				(1,541,000)
Other expenses		(13,000)																				(13,000)				(13,000)
Gain on acquisition of SAVSU		10,108,000																				10,108,000				10,108,000
Net loss		10,269,000		4,252,000		(19,161,000)		(19,161,000)		(24,465,000)		(26,346,000)		4,873,000		4,873,000		(14,909,000)		(21,472,000)		(4,640,000)		(45,938,000)		(1,657,000)	(25,005,000)
Depreciation								98,000								78,000		209,000		161,000		373,000		245,000		718,000	338,000
Stock-based compensation								531,000								373,000		1,349,000		748,000		2,179,000		1,131,000		3,043,000	1,519,000
Amortization of deferred rent related to lease incentives																32,000				63,000				95,000			127,000
Amortization of debt discount
Loss from equity method investment in SAVSU		(291,000)		(217,000)		(232,000)		(232,000)		(43,000)		(177,000)		(144,000)		(144,000)		(448,000)		(321,000)		(739,000)		(363,000)		(739,000)	(672,000)
Change in fair value of warrant liability		1,128,000		3,586,000		19,663,000		19,663,000		25,696,000		27,485,000		4,870,000		(4,870,000)		16,077,000		22,615,000		14,949,000		48,311,000		12,835,000	28,271,000
Accounts receivable, trade, net								(118,000)								23,000		632,000		1,145,000		372,000		1,678,000		290,000	2,024,000
Inventories								551,000								(10,000)		1,341,000		275,000		1,730,000		1,064,000		3,777,000	1,662,000
Prepaid expenses and other current assets								(6,000)								(12,000)		32,000		103,000		272,000		49,000
Accounts payable								553,000								(69,000)		(36,000)		168,000		377,000		343,000		768,000	(11,000)
Accrued compensation and other current liabilities								(302,000)								(101,000)		(20,000)		6,000		558,000		205,000
Deferred rent																(3,000)				(6,000)				(11,000)
Net cash provided by operating activities								1,146,000								392,000		1,079,000		955,000		2,216,000		1,763,000		1,213,000	2,348,000
Purchase of property and equipment								156,000								41,000		267,000		61,000		356,000		339,000		675,000	500,000
Net cash used in investing activities								(156,000)								(41,000)		(12,705,000)		(1,061,000)		(12,997,000)		(6,339,000)		(27,018,000)	(6,500,000)
Payments on equipment loan								4,000								2,000		8,000		5,000		12,000		9,000
Payments on finance lease obligation								4,000								3,000		7,000		7,000		9,000		10,000
Proceeds from exercise of common stock options and warrants								185,000								130,000		600,000		8,899,000		1,394,000		11,725,000		1,181,000	508,000
Payments of preferred stock dividends																106,000				213,000				306,000			436,000
Net cash provided by financing activities								177,000								19,000		585,000		7,611,000		1,329,000		30,294,000		1,596,000	28,146,000
Net increase (decrease) in cash and cash equivalents								1,167,000								370,000		(11,041,000)		7,505,000		(9,452,000)		25,718,000		(24,209,000)	23,994,000
Cash and cash equivalents – beginning of year		19,617,000		31,824,000		30,657,000		30,657,000		14,167,000		7,033,000		6,663,000		6,663,000		30,657,000		6,663,000		30,657,000		6,663,000		30,657,000	6,663,000
Cash and cash equivalents – end of year		21,205,000		19,617,000		31,824,000		31,824,000		32,381,000		14,167,000		7,033,000		7,033,000		19,617,000		14,167,000		21,205,000		32,381,000		6,448,000	30,657,000
Stock issued for services provided in prior period included in liabilities at year-end																36,000				36,000				36,000			36,000
Purchase of equipment with debt																18,000				18,000		146,000		18,000			18,000
Series A preferred stock dividends accrued not yet paid																																						80,000		93,000				106,000
Reclassification of warrant liabilities to equity upon exercise								73,000								29,000		400,000		9,639,000		1,695,000		17,509,000		1,749,000	19,378,000
Investment in equity investment SAVSU																				1,000,000				6,000,000
Payments for redemption of preferred stock																				1,063,000				1,063,000			4,250,000
Receivables converted to equity investment in SAVSU																				150,000				150,000			150,000
Purchase of property and equipment not yet paid								46,000										4,000		20,000		53,000		49,000		29,000	54,000
Stock issued for services
Write off of deferred financing costs
Proceeds from private equity transaction																								20,000,000			20,000,000
Deferred costs related to security issuance																								43,000
Legal fees for private equity transaction not yet paid																								43,000			44,000
Amortization of operating lease liability								43,000										87,000				132,000				(512,000)
Interest expense - finance type lease								2,000										2,000				2,000
Deferred rent																						1,000,000				1,000,000
Other liabilities																		(53,000)				(98,000)				(81,000)
Payments related to the Astero Bio Acquisition, net of cash acquired																		12,438,000				12,439,000
Investment in equity investment SAVSU																						453,000				1,655,000
Series A preferred stock dividends accrued not yet paid																						44,000
Stock consideration for 55.6% equity interest purchased																						19,932,000
Loss on disposal of property and equipment																						(13,000)
Gain on acquisition of SAVSU		10,108,000																				10,108,000				10,108,000
Other assets, net																						87,000
Cash acquired on acquisition of SAVSU																						1,251,000
Previously Reported [Member]
Cash and cash equivalents		21,205,000		19,617,000		30,657,000		31,824,000		32,381,000		14,167,000		6,663,000		7,033,000		30,657,000		6,663,000		30,657,000		6,663,000		30,657,000	30,657,000		21,205,000		19,617,000		31,824,000		31,824,000		30,657,000	32,381,000		14,167,000		7,033,000		7,033,000		6,663,000
Accounts receivable, trade, net of allowance for doubtful accounts of $68 and $0 at December 31, 2019 and 2018, respectively																													4,313,000		3,832,000		2,927,000					2,699,000		2,166,000		1,043,000
Inventories																													5,694,000		5,306,000		4,060,000					2,911,000		2,122,000		1,837,000
Prepaid expenses and other current assets																													855,000		384,000		346,000					298,000		352,000		331,000
Total current assets																													32,067,000		29,139,000		39,157,000					38,289,000		18,807,000		10,244,000
Leasehold improvements																													1,599,000		1,284,000		1,284,000					1,284,000		1,284,000		1,284,000
Furniture and computer equipment																													588,000		577,000		704,000					706,000		693,000		692,000
Manufacturing and other equipment																													2,247,000		1,733,000		1,803,000					1,511,000		1,230,000		1,195,000
Subtotal																													4,434,000		3,594,000		3,791,000					3,501,000		3,207,000		3,171,000
Less: Accumulated depreciation																													(2,298,000)		(2,276,000)		(2,424,000)					(2,234,000)		(2,163,000)		(2,084,000)
Property and equipment, net																													2,136,000		1,318,000		1,367,000					1,267,000		1,044,000		1,087,000
Equity method investment in SAVSU																													1,000,000		6,100,000		6,317,000					6,857,000		1,900,000		926,000
Long-term deposits and other assets																													36,000		136,000		36,000					36,000		36,000		36,000
Total assets																													84,228,000		51,742,000		48,073,000					46,449,000		21,787,000		12,293,000
Accounts payable																													1,570,000		876,000		1,264,000					1,090,000		843,000		586,000
Accrued expenses and other current liabilities																													642,000		204,000		142,000					162,000		173,000		204,000
Accrued compensation																													1,576,000		963,000		630,000					713,000		518,000		392,000
Deferred rent, current portion																															1,079,000		1,196,000					130,000		130,000		130,000
Total current liabilities																													4,944,000		3,093,000		2,701,000					2,095,000		1,664,000		1,312,000
Deferred rent, long-term																																						386,000		423,000		457,000
Warrant liability
Other long-term liabilities																													3,000		7,000		13,000					38,000		45,000		52,000
Total liabilities																													7,266,000		5,476,000		3,707,000				2,319,000	2,519,000		2,132,000		1,821,000
Commitments and Contingencies (Note 12)
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding at December 31, 2019 and 2018
Common stock, $0.001 par value; 150,000,000 shares authorized, 20,825,452 and 18,547,406 shares issued and outstanding at December 31, 2019 and 2018, respectively																													20,000		19,000		19,000					18,000		16,000		14,000
Additional paid-in capital																													137,392,000		116,013,000		114,951,000					115,776,000	[1]	92,654,000		84,518,000
Accumulated deficit																													(60,450,000)		(69,766,000)		(70,604,000)				(71,031,000)	(71,864,000)	[1]	(73,015,000)		(74,060,000)			(73,958,000)
Total shareholders’ equity																													76,962,000		46,266,000		44,366,000				43,148,000	43,930,000		19,655,000		10,472,000			10,092,000
Total liabilities and shareholders’ equity																													84,228,000		51,742,000		48,073,000					46,449,000		21,787,000		12,293,000
Lease liabilities, operating, current portion																													771,000		665,000		651,000
Lease liability - financing, current position																													14,000		14,000		14,000
Lease liabilities, operating, long-term																													753,000		806,000		980,000
Long-term lease liability - financing																													6,000		10,000		13,000
Intangible assets, net																													16,485,000		4,446,000
Goodwill																													28,351,000		9,524,000
Contingent consideration, current portion																													371,000		371,000
Contingent consideration, long term																													1,560,000		1,560,000
Assets held for rent, net																													2,976,000
Operating lease right-of-use assets, net																													1,177,000
Contingent consideration - long-term																													1,560,000		1,560,000
Revenue		6,604,000		6,701,000		5,770,000				5,293,000		5,178,000		3,815,000				12,471,000		8,993,000		19,075,000		14,286,000
Cost of product and rental revenue (exclusive of intangible assets amortization)		2,084,000		1,958,000		1,647,000				1,606,000		1,537,000		1,364,000				3,606,000		2,901,000		5,690,000		4,507,000
Research and development		1,309,000		739,000		372,000				312,000		325,000		346,000				1,111,000		671,000		2,420,000		983,000
Sales and marketing		1,259,000		928,000		848,000				725,000		641,000		612,000				1,776,000		1,253,000		3,035,000		1,978,000
General and administrative		2,258,000		2,118,000		2,204,000				1,455,000		1,390,000		1,353,000				4,321,000		2,744,000		6,579,000		4,199,000
Total operating expenses		7,201,000		5,782,000		5,279,000				4,098,000		3,893,000		3,675,000				11,061,000		7,569,000		18,262,000		11,667,000
Operating income (loss)		(597,000)		919,000		491,000				1,195,000		1,285,000		140,000				1,410,000		1,424,000		813,000		2,619,000
Change in fair value of warrant liability
Interest income		110,000		137,000		171,000				80,000		32,000		8,000				307,000		41,000		417,000		121,000
Interest expense		(1,000)		(1,000)		(3,000)				(1,000)		(1,000)		(1,000)				(4,000)		(1,000)		(5,000)		(4,000)
Loss from equity-method investment in SAVSU		(291,000)		(217,000)		(232,000)		(232,000)		(43,000)		(177,000)		(144,000)		(144,000)		(448,000)		(321,000)		(739,000)		(363,000)
Total other expense		9,913,000		(81,000)		(64,000)				36,000		(146,000)		(137,000)				(145,000)		(281,000)		9,768,000		(246,000)			(396,000)
Net loss (restated)		9,316,000		838,000		427,000		427,000		1,231,000		1,139,000		3,000		3,000		1,265,000		1,143,000		10,581,000		2,373,000			3,266,000
Less: Preferred stock dividends and accumulated deficit impact of preferred stock redemption										(80,000)		(93,000)		(106,000)						(200,000)				(279,000)
Net income (loss) attributable to common stockholders		9,316,000		838,000		427,000				1,151,000		1,046,000		(103,000)				1,265,000		943,000		10,581,000		2,094,000			$ 2,927,000
Diluted		$ 9,316,000		$ 838,000		$ 427,000				$ 1,151,000		$ 1,046,000		$ (103,000)				$ 1,265,000		$ 943,000		$ 10,581,000		$ 2,094,000
Basic (in dollars per share)		$ 0.47		$ 0.04		$ 0.02				$ 0.07		$ 0.07		$ (0.01)				$ 0.07		$ 0.06		$ 0.55		$ 0.13			$ 0.18
Diluted (in dollars per share)		$ 0.37		$ 0.03		$ 0.02				$ 0.05		$ 0.05		$ (0.01)				$ 0.05		$ 0.05		$ 0.43		$ 0.10			$ 0.14
Basic (in shares)		19,735,364		18,819,459		18,648,397				17,273,412		15,180,169		14,098,610				18,734,401		14,642,378		19,071,722		15,529,026
Diluted (in shares)		25,343,112		24,539,299		24,358,475				23,656,633		20,374,358		14,098,610				24,439,959		19,063,595		24,705,424		21,051,219
Change in fair value of warrant liability
Acquisition costs		$ 291,000		$ 39,000		$ 208,000												247,000				538,000
Income (loss) before provision for income taxes		9,316,000		838,000		427,000												1,265,000				10,581,000					3,266,000
Income tax (benefit)		0		0		0												0				0
Cost of product revenue (exclusive of intangible assets amortization)		2,084,000		1,958,000		1,647,000				$ 1,606,000		$ 1,537,000		$ 1,364,000				3,606,000		2,901,000		5,690,000		4,507,000
Amort of Intangibles																		104,000				465,000
Income (loss) before provision for income taxes		9,316,000		838,000		427,000												1,265,000				10,581,000					3,266,000
Income taxes		0		0		0												0				0
Other expenses		(13,000)																				(13,000)
Gain on acquisition of SAVSU		10,108,000																				10,108,000
Net loss		9,316,000		838,000		427,000		427,000		1,231,000		1,139,000		3,000		3,000		1,265,000		1,143,000		10,581,000		2,373,000			3,266,000
Depreciation								98,000								78,000		209,000		161,000		373,000		245,000
Stock-based compensation								606,000								373,000		1,252,000		748,000		1,907,000		1,131,000
Amortization of deferred rent related to lease incentives																32,000				63,000				95,000
Amortization of debt discount
Loss from equity method investment in SAVSU		(291,000)		(217,000)		(232,000)		(232,000)		(43,000)		(177,000)		(144,000)		(144,000)		(448,000)		(321,000)		(739,000)		(363,000)
Change in fair value of warrant liability
Accounts receivable, trade, net								(118,000)								23,000		632,000		1,145,000		372,000		1,678,000
Inventories								551,000								(10,000)		1,341,000		275,000		1,730,000		1,064,000
Prepaid expenses and other current assets								(6,000)								(12,000)		32,000		103,000		272,000		49,000
Accounts payable								553,000								(69,000)		(36,000)		168,000		377,000		343,000
Accrued compensation and other current liabilities								(302,000)								(101,000)		(20,000)		6,000		558,000		205,000
Deferred rent																(3,000)				(6,000)				(11,000)
Net cash provided by operating activities								1,146,000								392,000		1,079,000		955,000		2,216,000		1,763,000
Purchase of property and equipment								156,000								41,000		267,000		61,000		356,000		339,000
Net cash used in investing activities								(156,000)								(41,000)		(12,705,000)		(1,061,000)		(12,997,000)		(6,339,000)
Payments on equipment loan								4,000								2,000		8,000		5,000		12,000		9,000
Payments on finance lease obligation								4,000								3,000		7,000		7,000		9,000		10,000
Proceeds from exercise of common stock options and warrants								185,000								130,000		600,000		8,899,000		1,394,000		11,725,000
Payments of preferred stock dividends																106,000				213,000				306,000
Net cash provided by financing activities								177,000								19,000		585,000		7,611,000		1,329,000		30,294,000
Net increase (decrease) in cash and cash equivalents								1,167,000								370,000		(11,041,000)		7,505,000		(9,452,000)		25,718,000
Cash and cash equivalents – beginning of year		19,617,000		31,824,000		30,657,000		30,657,000		14,167,000		7,033,000		6,663,000		6,663,000		30,657,000		6,663,000		30,657,000		6,663,000		30,657,000	6,663,000
Cash and cash equivalents – end of year		21,205,000		19,617,000		31,824,000		31,824,000		32,381,000		14,167,000		7,033,000		7,033,000		19,617,000		14,167,000		21,205,000		32,381,000			30,657,000
Stock issued for services provided in prior period included in liabilities at year-end																36,000				36,000				36,000
Purchase of equipment with debt																18,000				18,000		146,000		18,000
Series A preferred stock dividends accrued not yet paid																																						80,000		93,000				106,000
Reclassification of warrant liabilities to equity upon exercise
Investment in equity investment SAVSU																				1,000,000				6,000,000
Payments for redemption of preferred stock																				1,063,000				1,063,000
Receivables converted to equity investment in SAVSU																				150,000				150,000
Purchase of property and equipment not yet paid								46,000										4,000		20,000		53,000		49,000
Proceeds from private equity transaction																								20,000,000
Deferred costs related to security issuance																								43,000
Legal fees for private equity transaction not yet paid																								43,000
Amortization of operating lease liability								43,000										87,000				132,000
Interest expense - finance type lease								2,000										2,000				2,000
Deferred rent																						1,000,000
Other liabilities																		(53,000)				(98,000)
Payments related to the Astero Bio Acquisition, net of cash acquired																		12,438,000				12,439,000
Investment in equity investment SAVSU																						453,000
Series A preferred stock dividends accrued not yet paid																						44,000
Stock consideration for 55.6% equity interest purchased																						19,932,000
Loss on disposal of property and equipment																						(13,000)
Gain on acquisition of SAVSU		10,108,000																				10,108,000
Other assets, net																						87,000
Cash acquired on acquisition of SAVSU																						1,251,000
Revision of Prior Period, Adjustment [Member]
Cash and cash equivalents
Accounts receivable, trade, net of allowance for doubtful accounts of $68 and $0 at December 31, 2019 and 2018, respectively
Inventories
Prepaid expenses and other current assets
Total current assets
Leasehold improvements
Furniture and computer equipment
Manufacturing and other equipment
Subtotal
Less: Accumulated depreciation
Property and equipment, net
Equity method investment in SAVSU
Long-term deposits and other assets
Total assets																													(439,000)		(439,000)
Accounts payable
Accrued expenses and other current liabilities
Accrued compensation
Deferred rent, current portion
Total current liabilities																													70,000		70,000
Deferred rent, long-term
Warrant liability																													41,771,000	[1]	44,194,000	[1]	48,106,000	[1]			28,516,000	50,425,000	[1]	32,599,000	[1]	14,725,000	[1]
Other long-term liabilities
Total liabilities																													41,332,000		43,755,000		48,106,000				28,516,000	50,425,000		32,599,000		14,725,000
Commitments and Contingencies (Note 12)
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding at December 31, 2019 and 2018
Common stock, $0.001 par value; 150,000,000 shares authorized, 20,825,452 and 18,547,406 shares issued and outstanding at December 31, 2019 and 2018, respectively
Additional paid-in capital	[1]																												814,000		(656,000)		(1,154,000)					(3,021,000)		(10,892,000)		(20,501,000)
Accumulated deficit																													(42,585,000)	[1],[2]	(43,538,000)	[1],[2]	(46,952,000)	[1]			(27,364,000)	(47,404,000)	[1]	(21,707,000)	[1]	5,776,000	[1]		907,000
Total shareholders’ equity																													(41,771,000)		(44,194,000)		(48,106,000)				$ (28,516,000)	(50,425,000)		(32,599,000)		(14,725,000)			$ (19,624,000)
Total liabilities and shareholders’ equity																													(439,000)		(439,000)
Lease liabilities, operating, current portion
Lease liability - financing, current position
Lease liabilities, operating, long-term
Long-term lease liability - financing
Intangible assets, net	[3]																												(430,000)		(430,000)
Goodwill	[3],[4]																												(9,000)		(9,000)
Contingent consideration, current portion	[4]																												70,000		70,000
Contingent consideration, long term	[4]																												(509,000)		(509,000)
Assets held for rent, net
Operating lease right-of-use assets, net
Contingent consideration - long-term	[4]																												$ (509,000)		$ (509,000)
Cost of product and rental revenue (exclusive of intangible assets amortization)		10,000	[2],[5]	10,000	[2],[5]													10,000				20,000	[2],[5]
Research and development		(277,000)	[2],[5]	(48,000)	[2],[5]	(13,000)	[2],[5]											(61,000)				(338,000)	[2],[5]
Sales and marketing		(9,000)	[2],[5]	17,000	[2],[5]	(11,000)	[2],[5]											6,000				(3,000)	[2],[5]
General and administrative		90,000	[2]	89,000	[2]	(51,000)	[2]											38,000				128,000	[2]
Total operating expenses		175,000		172,000		(75,000)												97,000				272,000
Operating income (loss)		(175,000)		(172,000)		75,000												(97,000)				(272,000)
Change in fair value of warrant liability		1,128,000	[1]	3,586,000	[1]	19,663,000	[1]	19,663,000	[1]	25,696,000	[1]	27,485,000	[1]	4,870,000	[1]	(4,870,000)	[1]	16,077,000	[1]	22,615,000	[1]	14,949,000	[1]	48,311,000	[1]		28,271,000
Loss from equity-method investment in SAVSU
Total other expense		1,128,000		3,586,000		(19,663,000)				(25,696,000)		(27,485,000)		4,870,000				(16,077,000)		(22,615,000)		(14,949,000)		(48,311,000)			(28,271,000)
Net loss (restated)		953,000		3,414,000		(19,588,000)		(19,588,000)	[1]	(25,696,000)		(27,485,000)		4,870,000		4,870,000	[1]	(16,174,000)	[1]	(22,615,000)	[1]	(15,221,000)	[1]	(48,311,000)	[1]		(28,271,000)
Less: Preferred stock dividends and accumulated deficit impact of preferred stock redemption
Net income (loss) attributable to common stockholders		(936,000)		2,587,000		(19,588,000)				(25,696,000)		(27,485,000)		4,870,000				(16,174,000)		(22,615,000)		(15,221,000)		(48,311,000)			$ (28,271,000)
Diluted		$ (454,000)		$ (293,000)		$ (19,588,000)				$ (25,696,000)		$ (27,485,000)		$ (179,000)				$ (16,174,000)		$ (22,614,000)		$ (15,221,000)		$ (48,311,000)
Basic (in dollars per share)		$ (0.05)		$ 0.14		$ (1.05)				$ (1.49)		$ (1.81)		$ 0.23				$ (0.87)		$ (1.54)		$ (0.79)		$ (3.11)			$ (1.74)
Diluted (in dollars per share)		$ (0.02)		$ (0.01)		$ (1.05)				$ (1.47)		$ (1.79)		$ (0.01)				$ (0.85)		$ (1.53)		$ (0.67)		$ (3.08)			$ (1.70)
Basic (in shares)
Diluted (in shares)						(5,710,078)				(6,383,221)		(5,194,189)						(5,705,558)		(4,421,217)		(5,633,702)		(5,522,193)
Change in fair value of warrant liability		$ (1,128,000)	[1]	$ (3,586,000)	[1]	$ (19,663,000)	[1]	(19,663,000)	[1]	$ (25,696,000)	[1]	$ (27,485,000)	[1]	$ (4,870,000)	[1]	4,870,000	[1]	$ (16,077,000)	[1]	$ (22,615,000)	[1]	$ (14,949,000)	[1]	$ (48,311,000)	[1]		$ (28,271,000)
Income (loss) before provision for income taxes		953,000		3,414,000		(19,588,000)												(16,174,000)				(15,221,000)					(28,271,000)
Income tax (benefit)		0		0		0												0				0
Cost of product revenue (exclusive of intangible assets amortization)		10,000	[2],[5]	10,000	[2],[5]													10,000				20,000	[2],[5]
Amort of Intangibles		361,000	[5]	104,000	[5]													104,000				465,000	[5]
Income (loss) before provision for income taxes		953,000		3,414,000		(19,588,000)												(16,174,000)				(15,221,000)					(28,271,000)
Income taxes		0		0		0												0				0
Gain on acquisition of SAVSU
Net loss		953,000		3,414,000		(19,588,000)		(19,588,000)	[1]	(25,696,000)		(27,485,000)		4,870,000		4,870,000	[1]	(16,174,000)	[1]	(22,615,000)	[1]	(15,221,000)	[1]	(48,311,000)	[1]		(28,271,000)
Depreciation
Stock-based compensation								(75,000)	[2]									97,000	[2]			272,000	[2]
Amortization of deferred rent related to lease incentives
Amortization of debt discount
Loss from equity method investment in SAVSU
Change in fair value of warrant liability		1,128,000	[1]	3,586,000	[1]	19,663,000	[1]	19,663,000	[1]	25,696,000	[1]	27,485,000	[1]	4,870,000	[1]	(4,870,000)	[1]	16,077,000	[1]	22,615,000	[1]	14,949,000	[1]	48,311,000	[1]		28,271,000
Accounts receivable, trade, net
Inventories
Prepaid expenses and other current assets
Accounts payable
Accrued compensation and other current liabilities
Deferred rent
Net cash provided by operating activities
Purchase of property and equipment
Net cash used in investing activities
Payments on equipment loan
Payments on finance lease obligation
Proceeds from exercise of common stock options and warrants
Payments of preferred stock dividends
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents – beginning of year
Cash and cash equivalents – end of year
Stock issued for services provided in prior period included in liabilities at year-end
Purchase of equipment with debt
Series A preferred stock dividends accrued not yet paid
Reclassification of warrant liabilities to equity upon exercise								73,000								$ 29,000		400,000		9,639,000		1,695,000		17,509,000
Investment in equity investment SAVSU
Payments for redemption of preferred stock
Receivables converted to equity investment in SAVSU
Purchase of property and equipment not yet paid
Proceeds from private equity transaction
Deferred costs related to security issuance
Legal fees for private equity transaction not yet paid
Amortization of operating lease liability
Interest expense - finance type lease
Deferred rent
Other liabilities
Payments related to the Astero Bio Acquisition, net of cash acquired
Investment in equity investment SAVSU
Series A preferred stock dividends accrued not yet paid
Stock consideration for 55.6% equity interest purchased
Loss on disposal of property and equipment
Gain on acquisition of SAVSU
Other assets, net
Cash acquired on acquisition of SAVSU

[1] Adjustments related to recording certain warrants as liabilities, see Note 2: "Restatement of Consolidated Financial Statements".

[2] Adjustments related to change in valuation method of market-based restricted stock awards.

[3] Adjustments related to change in valuation of in-process research and development acquired technology from the Astero acquisition

[4] Adjustments related to change in fair value of Astero contingent consideration at acquisition.

[5] Adjustments related to cost of revenue and intangible amortization were reclassified from research and development and sales and marketing to conform to the presentation of those operating expenses in the statement of operations for the year ended December 31, 2019